CLINUVEL added to Nasdaq International Designation
31 May 2016 CLINUVEL Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY)...
Read More
SCENESSE® treatment in Europe
17 May 2016 German Porphyria Expert Centres to start distribution of SCENESSE®...
Read More
CLINUVEL Newsletter - April 2016
4 April 2016 Clinuvel is arriving at a point many of our...
Read More
NICE Highly Specialised Technology workshop reviews SCENESSE®
23 March 2016 NICE’s technical team invited stakeholders with an interest in...
Read More
s.708A Notice
18 March 2016 Notice under section 708A(5)(e) of the Corporations Act 2001...
Read More
Appendix 3B
18 March 2016 Enclosed is a new issue announcement, application for quotation...
Read More
CLINUVEL accredits first European EPP expert centres
13 March 2016 CLINUVEL Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY)...
Read More
CLINUVEL placement of A$8.3 million completed successfully
13 March 2016 ** Not for release or distribution in the United...
Read More
Request for Trading Halt
11 March 2016 Pursuant to Listing Rule 17.1, Clinuvel Pharmaceuticals Ltd (CUV)...
Read More
Appendix 4D and Half Year Report
19 February 2016 Your Directors present their report on the company and...
Read More
CLINUVEL brief on European commercialisation
19 February 2016 CLINUVEL Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY)...
Read More